Back

In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampin against Brucella species

Abstract number: 1733_1530

Turan H., Arslan H., Uncu H., Azap O., Serefhanoglu K.

Objectives: Human brucellosis affecting any organ system is a prevalent public health problem with worldwide distribution. The high rate of relapse after treatment with conventional drugs underlines the need for new anti-Brucella antibiotics. We therefore measured the in vitro activity of a new antimicrobial agent, tigecycline and compared it with the activity of established antimicrobials. No data exists regarding this issue.

Methods: A total of 82 strains of Brucella species were tested. All of these were obtained from blood and bone marrow cultures. The in vitro antimicrobial activities of tigecycline, doxycycline, ciprofloxacin, and rifampin were determined by E-test method.

Results: Doxycycline demonstrated the lowest MIC50 and MIC90 values, followed by tigecycline, ciprofloxacin, and rifampin. The MIC50 and MIC90 values of antibiotics for the strains of B. melitensis are shown in the Table. While all isolates were susceptible to ciprofloxacin and doxycycline, intermediate resistance to rifampin was detected in 19 (23%) isolates.

In vitro activities of tigecycline, doxycycline, ciprofloxacin and rifampin against 82 strains of B. melitensis

AntibioticRange (mg/mL)MIC50MIC90
Tigecycline<0.016–0.1250.0640.125
Doxycycline<0.016–0.1250.0160.047
Ciprofloxacin0.047–0.250.0940.19
Rifampin0.25–20.751.50

Conclusion: In conclusion, in the present in vitro study, the MIC values of tigecycline, a novel tetracycline analogue, were assessed for the first time against strains of Brucella, and the MIC values of tigecycline were found to be lower than those of rifampin and ciprofloxacin, but were greater than those of doxycycline, a major component of currently available regimens in Brucella infections. Considering the fact that Brucellae are intracellular pathogens, in vivo studies are needed to fully evaluate therapeutic potential of tigecycline in brucellosis.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top